The Chairman of one of the busiest Contract Development and Manufacturing Organizations (CDMOs), Charles River Laboratories, has warned that biopharma companies will likely cut drug discovery activity in the coming months due to a lack of demand recovery and softening trends. This will result in a negative impact on the growth prospects for the second half of the year. Other global biopharma companies are likely to restructure, cut budgets, and prune pipelines due to the Inflation Reduction Act, patent expirations, or both.
Identity Theft Surges as Criminals Deploy Advanced Tactics to Steal Personal Data
In 2024, identity theft surged, leading to over $16 billion in U.S. losses. Criminals exploit generative AI, deepfakes, and sophisticated phishing tactics, with synthetic identity
